# Study of Erlotinib and Metformin in Triple Negative Breast Cancer

> **NCT01650506** · PHASE1 · COMPLETED · sponsor: **Columbia University** · enrollment: 8 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Metformin
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01650506
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650506, "Study of Erlotinib and Metformin in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01650506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*